Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NMRC-M3V-Ad-PfCA
- Development stage
- Phase 2
- Lead developer
- Precigen
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**NMRC-M3V-Ad-PfCA** is an investigational multivalent, non-replicating human adenovirus serotype 5 vaccine developed by the Naval Medical Research Center for prevention of *Plasmodium falciparum* malaria. The product combines two recombinant Ad5 vectors: one encoding *P. falciparum* circumsporozoite protein and one encoding apical membrane antigen 1. By expressing these parasite antigens in vaccinated individuals, it is intended to elicit humoral and cellular immune responses against pre-erythrocytic and blood-stage malaria parasites. In a Phase 1/2a controlled human malaria infection study, the vaccine was reported to be safe, well tolerated, and immunogenic, but it did not provide protective efficacy against controlled human malaria infection.
- Other names
- AdPfCANMRC-Multi-antigen Multi-stage Malaria Vaccine-Adenovectored-Plasmodium falciparum CSP and AMA1 antigens
02
Targets
CSP (Circumsporozoite protein)AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on NMRC-M3V-Ad-PfCA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NMRC-M3V-Ad-PfCA.